Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
https://doi.org/10.37489/2587-7836-2022-1-3-8
Abstract
The effect of memantine (1 and 10 mg/kg/day), ladasten (50 mg/kg/day) and cyclantane (10 mg/kg/day) on the behavior of CD-1 mice differing in the phenotype of attention stability in the "closed enriched cross maze" test after three days of intraperitoneal administration was studied. It was found that in a subpopulation of mice with an initial attention deficit, these aminoadamantane derivatives partially restored the level of attention. The drugs equally worsened attention in a subpopulation with an initially high attention index by 40–47 % relative to the control, which indicates the absence of selectivity of the effect of these drugs with respect to attention deficit. However, this effect was not accompanied by a change in exploratory and locomotor activity, which makes it possible to make an assumption about the prospects for further study of the pharmacological effects of adamantane derivatives and optimization of their dose and duration of administration.
Supporting agencies: This study was performed within the framework of State Task No. 122020400052-2 “Pharmacological correction of cerebrovascular and cognitive disorders with neuroreceptor analysis”
About the Authors
N. A. Sukhorukova
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Nataliya A. Sukhorukova, Junior researcher
Laboratory of radioisotope research metho
SPIN code: 2656-4174
Moscow
R. M. Salimov
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Ramiz M. Salimov, Dr. Sci. Biological, Lead specialist
Laboratory of radioisotope research methods
Moscow
G. I. Kovalev
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Georgy I. Kovalev, Dr. Sci. (Med.), professor, Head of the Laboratory
Laboratory of radioisotope research methods
SPIN code: 8461-8814
Moscow
References
1. Núñez-Jaramillo L, Herrera-Solís A, Herrera-Morales W. V. ADHD: Reviewing the causes and evaluating solutions. J Pers Med. 2021;11 (3): 166. DOI: 10.3390/jpm11030166.
2. Faraone S. V. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit / hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018; 87: 255–270. DOI: 10.1016/j.neubiorev.2018.02.001.
3. Hennissen L, Bakker M. J., Banaschewski T. et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017; 31(3): 199–215. DOI: 10.1007/s40263-017-0410-7.
4. Морозов И. С. Фармакология адамантанов / И. С. Морозов, В. И. Петров, С. А. Сергеева. – Волгоград: Волгоградская медицинская академия, 2001. – 320 с. [Morozov I. S., Petrov V. I., Sergeeva S. A. Pharmacology of adamantans. Volgograd: Volgograd Medical Academy; 2001. (In Russ).].
5. Salimov R. M., Kovalev G. I. Effect of atomoxetine on behavior of outbred mice in the enrichment discrimination test. Journal of behavioral and brain science. 2013; 3 (02): 210–216. DOI: 10.4236/jbbs.2013.32022.
6. Ковалёв Г. И. Нейрорецепторный профиль и поведение субпопуляций мышей CD-1, различающихся устойчивостью внимания / Г. И. Ковалёв [и др.] // Нейрохимия. –2020. – ; 37(1): 15–23. [Kovalev G. I., Salimov R. M., Sukhorukova N. A., Kondrakhin E. A., Vasil'eva E. V. Neuroreceptor profile and behavior of CD-1 mice subpopulations with different attention stability. Neurochemical Journal. 2020; 37 (1): 15–23. (In Russ).]. DOI: 10.31857/S1027813320010148.
7. Ковалёв Г. И. Влияние пантогама и атомоксетина на устойчивость внимания и распределение дофаминовых D2 и ГАМКВ-рецепторов у мышей с моделью дефицита внимания / Г. И. Ковалёв [и др.] // Биомедицинская химия. – 2021. – 67 (5): 402–410. [Kovalev G. I., Sukhorukova N. A., Vasileva E. V., Kondrakhin E. A., Salimov R. M. Influence of pantogam and atomoxetine on attention stability and distribution of dopamine D2 and GABAB receptors in the attention deficit mouse model. Biomeditsinskaya khimiya. 2021; 67(5): 402–410. (In Russ).]. DOI: 10.18097/PBMC20216705402.
8. Ковалёв Г. И. Анализ поведенческих и нейрорецепторных эффектов атомоксетина и фенибута у мышей CD-1 с различной устойчивостью внимания / Г. И. Ковалёв [и др.] // Экспериментальная и клиническая фармакология. – 2021. – 84 (4): 3–11. [Kovalev G. I., Sukhorukova N. A., Vasileva E. V., Kondrakhin E. A., Salimov R. M. Analysis of behavioral and neuroceptor effects of atomoxetine and phenibut in CD-1 mice subpopulations diverging in sustained attention. Eksperimental'naya i klinicheskaya farmakologiya. 2021; 84 (4): 3–11. (In Russ).]. DOI: 10.30906/0869-2092-2021-84-4-3-11.
9. Ковалёв Г. И. Влияние пирацетама на рецепторные системы мозга мышей CD-1 с разным фенотипом устойчивости внимания / Г. И. Ковалёв [и др.] // Химико-фармацевтический журнал. – 2021. – 55 (8): 10–14. [Kovalev G. I., Sukhorukova N. A., Kondrakhin E. A., Vasil'eva E. V., Salimov R. M. Influence of piracetam on the brain receptors in CD-1 mice with different attention stability phenotypes. Pharmaceutical Chemistry Journal. 2021; 55 (8): 10–14. (In Russ).]. DOI: 10.30906/0023-1134-2021-55-8-10-14.
10. Ковалёв Г. И. Субхроническое введение семакса повышает устойчивость внимания у мышей CD-1 через модуляцию D2-дофаминовых рецепторов префронтальной коры мозга / Г. И. Ковалёв [и др.] // Экспериментальная и клиническая фармакология. – 2021. – 84 (6): 3–10. [Kovalev G. I., Sukhorukova N. A., Kondrakhin E. A., Vasil'eva E. V., Salimov R. M. Subchronic administration of semax increases attention stability in CD-1 mice via modulation D2-dopamine receptors in the prefrontal cortex. Eksperimental'naya i klinicheskaya farmakologiya. 2021; 84 (6): 3–10. (In Russ).]. DOI: 10.30906/0869-2092-2021-84-6-3-10.
Review
For citations:
Sukhorukova N.A., Salimov R.M., Kovalev G.I. Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability. Pharmacokinetics and Pharmacodynamics. 2022;(1):3-8. (In Russ.) https://doi.org/10.37489/2587-7836-2022-1-3-8
Views:
330
Email this article 